Glioblastoma |
EGFRvIII |
18 |
National Cancer Institute |
1/2 |
Completed |
Patients received conditioning chemotherapy with
cyclophosphamide and fludarabine followed by intravenous infusion of
Aldesleukin. |
NCT01454596 |
Glioblastoma |
EGFRvIII |
7 |
University of Pennsylvania |
1 |
Active,
Not Recruiting |
Patients receive combination therapy with pembrolizumab
(PD-1 Inhibitor) and CAR T-cells. |
NCT03726515 |
R/R Brain Neoplasm |
IL13Rα2 |
18 |
City of Hope Medical Center |
1 |
Recruiting |
Prior to CAR T therapy, patients receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine intravenously. |
NCT04510051 |
R/R Glioblastoma |
IL13Rα2 |
60 |
City of Hope Medical Center |
1 |
Recruiting |
Patients receive nivolumab and ipilimumab intravenously,
then receive CAR-T cells via Rickham catheter (ICV/intracranital ICT). |
NCT04003649 |
Diffuse Intrinsic Pontine and Midline Glioma |
B7-H3 |
70 |
Seattle
Children’s Hospital |
1 |
Recruiting |
CAR-T cells will be given via a
CNS catheter into the tumor resection cavity or ventricular system. |
NCT04185038 |
R/R Glioblastoma |
B7-H3 |
12 |
Zhejiang University School of Medicine |
1 |
Recruiting |
Patient receive Temozolomide orally, then CAR-T cells
will be administrated via intratumoral or Intracerebroventricular
injection. |
NCT04385173 |
R/R Brain Tumor |
HER2 |
28 |
Baylor College of Medicine |
1 |
Recruiting |
CAR-T cells will be administered into the tumor, tumor
resection cavity, and/or cerebrospinal fluid (CSF). |
NCT02442297 |
Recurrent Glioblastoma |
MMP2 |
36 |
City of Hope Medical Center |
1 |
Recruiting |
Patients receive chlorotoxin
(EQ)-CD28-CD3zeta-CD19t-expressing CAR-T cells via dual delivery |
NCT04214392 |
High Grade Glioma |
GD2 |
32 |
Baylor College of Medicine |
1 |
Recruiting |
Patients receive lymphodepletion chemotherapy consisting of
cyclophosphamide and fludarabine. |
NCT04099797 |